Xenetic Biosciences (XBIO)

• Market cap: $3.75M
• 1 day: 0.83%
• 5 days: 2.10%
• 1 month: -33.79%
• 3 months: -42.69%
• 6 months: -33.97%
• Year to date: -40.00%
• 1 year: -37.05%
• 5 years: -72.39%
• 10 years: -99.51%
• Sector: Healthcare
• Industry: Biotechnology

About: Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.

Employees: 2

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

200% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 2

68% more capital invested

Capital invested by funds: $212K [Q3] → $356K (+$144K) [Q4]

33% more funds holding

Funds holding: 9 [Q3] → 12 (+3) [Q4]

2.64% more ownership

Funds ownership: 3.16% [Q3] → 5.81% (+2.64%) [Q4]

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2